ABCL575 is a novel, half-life extended anti-OX40L monoclonal antibody that is being developed for the treatment of ...

Kymera Therapeutics Inc (KYMR) showcases robust financial health and strategic pipeline advancements amid competitive ...

Q1 2025 Earnings Conference Call May 9, 2025 10:00 AM ETCompany ParticipantsJustine Koenigsberg - Vice President ...

Q1 2025 Earnings Call Transcript May 9, 2025 Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.82, expectations were $-0.92. Justine Koenigsberg: Good morning, and welcome to ...

SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis ...

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported ...

In April 2025, Areteia Therapeutics announced a study will assess the efficacy and safety of dexpramipexole as an adjunctive ...

Effective mucosal immunity in the intestine involves a fine balance between tolerance of the microbiome, recognition and elimination of pathogens, and inflammatory tissue injury. The anti-inflammatory ...

Cytokines are proteins, peptides or glycoproteins secreted by lymphocytes and monocytes that regulate immune responses, haematopoiesis and lymphocyte development. Cytokines include interleukins ...

In mammals, the most important facilitators of leukocyte migration are a class of chemoattractant cytokines (chemokines) that bind a large subfamily of the G protein–coupled receptors.

What is Known About the Estrogen Deficiency of Menopause & Specific Autoimmune Diseases It is known that many natural, pathological and therapeutic conditions can change serum estrogen levels ...

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to ...